Background. Data on rotavirus burden among children in the 15 newly independent states of the former Union of Soviet Socialist Republics, particularly contemporary data from poorer countries, are not widely available. These data are desired by policy makers to assess the value of rotavirus vaccination, especially since the GAVI Alliance approved financial support for the region's eligible countries. The Rotavirus Surveillance Network was established to provide these data.
virus vaccine (Rotarix; GlaxoSmithKline) or the pentavalent bovine-human reassortant vaccine (RotaTeq; Merck), is considered to be the best strategy for reducing morbidity and mortality associated with rotavirus. Studies on vaccine efficacy that were conducted in the Americas and Europe have prompted the World Health Organization (WHO) to recommend rotavirus vaccination in these 2 regions [4] .
These rotavirus vaccines have been licensed in 1100 countries throughout the world, and some countries have introduced the vaccines in their national immunization programs (eg, countries in Latin America, the European Union, and the United States). The 15 newly independent states (Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan [Estonia, Latvia, and Lithuania have become members of the European Union]) that emerged from the former Union of Soviet Socialist Republics could potentially introduce rotavirus vaccine in the near future. Over 17 million children aged !5 years reside in these countries [5] . Eight of the countries (Armenia, Azerbaijan, Georgia, Kyrgyzstan, Republic of Moldova, Tajikistan, Ukraine, and Uzbekistan) are eligible for financial support from the GAVI Alliance (formerly known as the Global Alliance for Vaccines and Immunization) to purchase new vaccines, including rotavirus vaccine. Policy makers from each of these countries will need to assess the value and cost of introducing rotavirus vaccine for children. One critical component of the decision-making process will be understanding the burden of severe rotavirus disease. Contemporary data on the burden and epidemiology of rotavirus disease in the region and the genotypes of circulating strains are limited.
To provide these data, the WHO, PATH, and the Centers for Disease Control and Prevention helped Ministries of Health establish the Rotavirus Surveillance Network (RSN) in GAVIeligible countries in the WHO European Region. This network will compliment the activities in the rotavirus strain surveillance system established in Western Europe (EUROROTANET). Data from RSN will also raise awareness of rotavirus disease among persons who frequently care for infected children but who are not able to identify the pathogen, including clinicians, parents, and managers of public health programs. In addition, the RSN will be a valuable platform for assessing rotavirus vaccine performance after introduction and for monitoring changes in strain distribution over time.
In this article, we review studies published from 1980 through 2007 that investigated rotavirus gastroenteritis among children in the newly independent states. We also present data from the first year of surveillance for rotavirus gastroenteritis among hospitalized children that was conducted by 3 GAVIeligible newly independent states in the RSN.
METHODS

Literature Review
We attempted to identify all articles published in the scientific and medical literature from 1 January 1980 through 30 September 2007 that described the rotavirus burden among children in the newly independent states. Articles in various languages of the region were included. PubMed and EMBASE were searched using the terms "rotavirus," "gastroenteritis," "diarrhea," "disease burden," "surveillance," and "infection," as well as country names. Bibliographies of the articles were reviewed for additional relevant publications, and country technical reports were reviewed when available. For this review, we included studies that reported rotavirus detection results for a minimum of 100 stool samples from children aged !14 years (a standard age-group classification used in publications from this region) that were tested for rotavirus with use of electron microscopy, latex agglutination, enzyme immunoassay (EIA), polyacrylamide gel electrophoresis, or reverse-transcription polymerase chain reaction (RT-PCR). For studies that reported results with use of 11 detection method, we reported the results of testing with only 1 method with use of the following hierarchy: (1) RT-PCR, (2) EIA, (3) polyacrylamide gel electrophoresis, and (4) electron microscopy or latex agglutination. When publications from the same investigators and location greatly overlapped with regard to the period of data collection, the study with the most recent data or with more information on the burden of disease was selected. Studies that reported that the duration of sample collection was !3 months were excluded.
Studies were classified on the basis of severity of disease (inpatient, outpatient, and combined) and duration of the sample collection period (у12 months, 3-11 months, or not specified). From each publication, we extracted the proportion of cases of gastroenteritis due to rotavirus. When the value was not explicitly stated, we calculated it by dividing the number of rotavirus-positive specimens by the total number of specimens tested. The results were categorized by country, age group (!2, !5, and !14 years of age), and calendar month, as available. Median estimates of the proportion of gastroenteritis cases attributable to rotavirus were calculated for the studies overall. For studies that reported results for 11 age group, we used the result from the group closest to age !5 years for the median calculation.
RSN
Proposals for establishing an RSN site(s) were solicited by the WHO Regional Office for Europe from the Ministries of Health of the region's GAVI-eligible countries. Consultants visited the countries that expressed interest, to help determine the capability of site staff to perform rotavirus surveillance and rotavirus EIA testing, assess equipment and budget needs, and provide training. Rotavirus surveillance was established at sentinel hos- 
Surveillance and Laboratory Methods
Surveillance methods followed those outlined in the WHO generic protocol for hospital-based surveillance of rotavirus gastroenteritis [6] . On days when surveillance was scheduled to be conducted, hospital admission logs were reviewed to identify all children aged !60 months who were admitted for AGE, defined as the occurrence of at least 3 watery or looser-thannormal stools in a 24-h period, with a duration of р7 days on the day of hospital admission. Children who were hospitalized for at least 1 night were eligible for enrollment. Standard demographic and clinical data were collected on each enrolled child; in addition, site investigators could adapt data collection forms to gather additional information (eg, use of oral rehydration treatment before hospitalization) that they deemed valuable. From each child, a whole stool sample was collected in a screw-top container within 48 h of hospital admission. Stool samples were refrigerated at the hospital until delivery to the testing lab; samples were delivered in a cold box usually once weekly.
At the testing laboratory, stool samples were refrigerated for a maximum of 1 month until testing was performed. Stool samples that could not be tested within 1 month after collection were aliquoted and frozen at Ϫ20ЊC for a maximum of 4 months until testing could be performed. Rotavirus detection was performed by specific laboratory personnel involved in the RSN by use of commercial IDEIA enzyme-linked immunosorbent assay kits (OXOID [Ely]). Testing was performed according to the manufacturer's instructions, which were translated into the Russian language. Results were determined photometrically using EIA plate readers and were reported to the hospital surveillance coordinator. Whenever possible, a second aliquot of each stool specimen was stored at the testing laboratory at Ϫ20ЊC to allow further testing, including rotavirus strain identification. In mid-2007, ∼80 samples positive for rotavirus and 20 samples negative for rotavirus by EIA were randomly selected at each site and sent to the Enteric Virus Unit, Virus Reference Department, Centre for Infections, Health Protection Agency, in London, United Kingdom, to assess EIA performance at the originating laboratory and to characterize the circulating strains. Strain typing was performed by RT-PCR using established methods [7] . All surveillance protocols were submitted to the WHO Ethical Review Committee and were deemed to be exempted from review.
RESULTS
Literature Review
Burden of disease. We identified and reviewed 89 publications from the 15 countries. Eighty-two studies (92%) were published in Russian, 3 (4%) in a country's non-Russian native language, and 4 (4%) in English. A total of 32 publications from 8 countries met our inclusion criteria (Tables 1 and 2 ). Most publications (21 [66%] of 32) were from 1 country, the Russian Federation. Samples for rotavirus testing were collected within the most recent decade (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) in only 6 (19%) of the studies. Rotavirus was detected using EIA in 15 publications (47%), electron microscopy in 12 (38%), RT-PCR in 3 (9%), RNA-polyacrylamide gel electrophoresis in 1 (3%), and latex agglutination in 1 (3%).
Among the 17 studies that included only inpatients for which samples were collected over a period у12 months, the median proportion of rotavirus detection was 33% (range, 16%-65%) ( Table 1) . For the 5 studies involving inpatients that had a sample collection period of 3-11 months, the median proportion of rotavirus detection was 37% (range, 24%-67%) ( Table  2) . Seven additional studies involving inpatients did not report the duration of the sample collection period (median detection, 30%; range, 17%-74%). Finally, 3 other studies included outpatients or did not specify patient type (Table 2) .
Seasonality. Three studies provided rotavirus detection rates by calendar month ( Figure 2) ; higher detection was observed from December through March (Belarus) [8] , October through March (northwestern Russian Federation) [17] , and January through April (western Russian Federation) [23] . Other studies did not provide detailed results but described that higher rotavirus detection occurred during particular seasons or months: autumn (Tajikistan) [39] , autumn and winter (Georgia [11, 12] and western Russian Federation [16] ), autumn through spring (Moldova) [14] , winter (northwestern Russian Federation) [26, 28, 31, 33] , or winter and spring (western and southwestern Russian Federation [19, 20] , Moldova [15] , and Belarus [9, 40] ).
Rotavirus serotypes/genotypes. The results of 4 studies that characterized rotavirus strains with use of G serotyping or G and P genotyping assays are summarized in table 3. G1 was the most common strain identified in 3 studies [10, 21, 22] . In a study from Birobidzhan in eastern Russian Federation [38] , almost all isolates were G3P [8] . One additional study [41] described the changes in strain types in Nizhniy Novgorod (western Russian Federation) over a 19-year period: G1P [8] predominated in the mid-1980s, 3 different genotypes (G1P [8] , G3P [8] , and G4P [8] ) were frequently detected during the first half of the 1990s, and G1P [8] again predominated during the late 1990s and early 2000s.
RSN
Burden of disease. In 2007, 3374 (67%) of the 5008 children eligible for enrollment were recruited at the 4 sentinel hospitals in the 3 countries combined ( Table 4 ). The mean monthly proportion of children eligible for enrollment who were enrolled in the surveillance system ranged from 45% to 92%, depending on the site. Overall, rotavirus was detected in 1425 (42%) of 3374 samples from the enrolled children (those aged !5 years and hospitalized for AGE). Rotavirus was detected in 38% of enrolled children in Tajikistan, 40% in Georgia, and 41% and 49% in Odessa and Kyiv (Ukraine), respectively (mean site detection rate, 42%; median, 40%). Age (in years) was available from Ukraine and Georgia sites. Of the hospitalized children with rotavirus aged !5 years, 740 (64%) of 1158 were aged !2 years.
Seasonality. Hospitalizations for rotavirus gastroenteritis were detected year-round at each site, with variability by season (Figure 2 ). In Tajikistan, peak detection (58%-65%) occurred from October through December. Detection was highest during the winter and spring months at the other 3 sites (Georgia: 52%-64% during December-April; Kyiv, Ukraine: 70% in December and 54%-76% during February-May; Odessa, Ukraine: 61%-63% in November and December and 41%-46% during March-May). Rotavirus accounted for у14% of cases of AGE among enrolled children during each month at each site, except in Georgia during June, when it accounted for only 6%. In Odessa, rotavirus was detected in у23% of samples from children each month.
Rotavirus genotypes. Strains were able to be typed in 323 samples. The most common rotavirus strain was G1P [8] (102 The upper age limit was not clearly described, but the majority of children tested were aged less than the stated age. [32%]), followed by G9P [8] (Table 3 ). More than 1 G type was detected in 13 samples (4%). G12 was the sole G type in 7 samples (2%) and was combined with another type in 4 additional samples. G10 was the sole G type in 1 sample (0.3%) and was combined with G12 in another sample.
DISCUSSION
As in every region studied, rotavirus exacts a heavy toll among young children living in the newly independent states. Data from previously published reports were primarily from 1 country (the Russian Federation) and suggested that rotavirus was responsible for ∼33% of hospitalizations for gastroenteritis among children in various age groups. Using a standardized WHO surveillance protocol, 4 sites in the region's new RSN documented that 42% of hospitalizations for acute gastroenteritis among children aged !5 years were attributable to rotavirus.
As our literature review indicates, several investigators in the region have worked to improve detection and understanding of the pathogen and its epidemiology. Although many previous studies provide useful information, only a limited number were described as prospectively evaluating all children with AGE or a systematically selected sample within the age group at high risk of disease over at least a 1-year period. Many of the results presented here were derived from studies in which the primary objective was to compare the performance of rotavirus detection assays; such studies began at the level of the laboratory rather than the level of the patient. Many studies were performed during the 1980s, when electron microscopy was used, which is less sensitive than currently available standardized EIAs. The few recent reports that were found were primarily from the Russian Federation. Furthermore, many studies provided results only for the group of children aged !14 years, limiting applicability toward understanding the burden among young children at greatest risk of severe rotavirus disease, and some presented results only for children with AGE of unknown etiology.
The RSN provides a platform for collecting epidemiological and clinical data and stool samples in a standardized way and for detecting rotavirus in stool samples with a standardized, sensitive assay to accurately determine the current burden of rotavirus disease. Such standardization allows comparisons of results among countries and regions, as well as changes over time. The data from the RSN indicate that ∼2 of 5 children aged !5 years who are hospitalized with AGE in Georgia, Tajikistan, and Odessa, Ukraine, and ∼1 of 2 in Kyiv, Ukraine, are hospitalized because of rotavirus infection. These results are somewhat higher than the median found in the review of the region's literature, at least in part because of the reasons described above. However, these results are similar to the higher results of 44% obtained during the first year (2001-2002) of surveillance through the Asian Rotavirus Surveillance Network, which also used the WHO rotavirus surveillance protocol [42] . A recent publication from collaborators in the AGE observational study in 7 European countries (REVEAL) demonstrated that rotavirus caused at least 53% of hospitalizations in each of the countries among children aged !5 years who were hospitalized for AGE during 2004-2005, with a maximum value of 69% detected in Italy [43] . The proportional estimate of severe rotavirus disease among all causes of severe gastroenteritis depends, in part, on the frequency of infection due to other enteric pathogens among children in the country, as well as on hospitalization practices for children who present with AGE. Determining population-based rates of severe rotavirus disease, as was done in REVEAL, would be a valuable next step for RSN sites that can accurately enumerate their population under surveillance.
Data from the RSN on the seasonality of rotavirus disease augment the data in the published literature from the region. As in other temperate zones, seasonality was demonstrated in the newly independent states region, but unlike the clear winter peak observed in some western European countries and the Americas [44] , rotavirus detection did not peak only in the winter months in all newly independent states. The rotavirus season appears to peak earlier in the region's southeastern area (eg, October-December in Tajikistan) and continues later in locations further north and west (eg, through May in Ukraine). Hospitalizations for rotavirus disease occurred every month of the year at each of the RSN sites.
The most common rotavirus genotype identified in the RSN in 2007 was G1P [8] (32%). Two earlier studies from the region reported a G1 prevalence similar to this result, and another reported a higher prevalence. With exclusion of isolates with 11 genotype, G1-G4 and G9 types combined made up 97% of the RSN isolates, similar to the proportion in Europe (у96%) [45, 46] and globally (190%) [47] . The relatively high prevalence (20%) of the "emerged" strain G9P [8] found in the RSN has been reported from several other areas [45, 47] . Some unusual genotypes (G1P [4] , G4P [4] , G10P [6] , G12P [6] , and G12P [8] ) were also detected in the RSN. These may represent zoonotic introduction or reassortants that naturally occur among human rotavirus genotypes [47] [48] [49] . Mixed infections with 11 rotavirus genotype were detected in 4% of the RSN samples, in the range of the overall mixed infections estimates of 2%-5% detected in Europe, Australia, and North America and lower than the 10%-15% estimated from Africa, Asia, and South America [47] . In the recent European REVEAL study, however, no mixed rotavirus infections were identified among the 1031 samples positive for rotavirus by EIA that were genotyped, but this finding may be associated with the methodology used for virus characterization [45] . Three samples from the RSN contained the unusual genotype P [9] in combination with another P type, representing an opportunity for reassortment between human and animal rotavirus strains. It is possible that the greater diversity of cocirculating genotypes detected in the RSN samples may be attributable, in part, to improved, more-sensitive methods that include use of primers for detecting genotypes that were not available in the earlier studies. The dynamics of genotype persistence versus change, by area and by time, are not well understood [47, 50] . Genotyping results from a larger number of samples collected over a longer period in the RSN countries will be a valuable contribution to the region's literature.
As policy makers wrestle with important decisions regarding timeline and financing for the introduction of new vaccines, cost-benefit data become increasingly essential. Data on the burden of rotavirus disease from each country or from similar countries will be a critical component of these analyses. A costeffectiveness analysis has already been conducted in Uzbekistan, where a rotavirus vaccine program was estimated to avert US$369,000 in direct and indirect costs for rotavirus hospitalizations alone in 1 birth cohort and was projected to be costeffective with vaccine prices in the range of US$2-25 per child [24] .
In conclusion, in view of the heavy burden of rotavirus disease in the newly independent states that was revealed by this epidemiological surveillance and the high clinical efficacy of the 2 available rotavirus vaccines [51] [52] [53] , introducing rotavirus vaccine and achieving coverage at levels similar to those achieved with other routine infant vaccines could prevent a substantial component of the total diarrhea-associated morbidity and mortality in this region. In addition, costs of hospitalization, lost productivity, and resource expenditure by families that are associated with severe gastroenteritis could be reduced significantly by the introduction of these vaccines. Rotavirus vaccine would be a valuable public health asset in the newly independent states, especially in the 8 GAVI-eligible countries, where it is now available at heavily subsidized prices.
Other countries in the European region need to conduct costbenefit analyses for their own populations to assess the potential impact of the vaccine. Finally, postmarketing surveillance built on the foundation of the RSN will permit countries to document the impact of vaccine introduction on severe rotavirus disease.
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